Document is current

Article History

Received: 29 March 2021

Accepted: 7 July 2021

First Online: 24 July 2021

Declarations

:

: IVL reports institutional honoraria from Pfizer, Astra-Zeneca, and Amgen. IEK reports research support (paid to his institution) from Genentech/Roche and Pfizer, has received fees from Novartis and Merck for Data Monitoring Board participation, received honoraria from Celltrion, and has received consulting fees from Bristol Meyers Squibb, Daiichi/Sankyo, Macrogenics, Context Therapeutics, Taiho Oncology, Genentech/Roche, Seattle Genetics, and AstraZeneca. NU reports research support (to institution) from Genentech, Merck, Pfizer, Seattle Genetics; Consultant/ad board: Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Denali Therapeutics, California Institute for Regenerative Medicine, Prelude Therapeutics. RAF reports research support (to institution, no salary support): Eisai and Puma. SJI has received institutional research funding from Abbive, Astrazeneca, Genetech, Merck and OcnoPep, and fees from Seattle genetics, Novartis, Puma. N.W. reports advisory relationships and consulting with Eli Lilly and Co.; advising and stockholding interest in Relay Therapeutics; and grant support from Puma Biotechnology. JB-B is now employed by Cellarity, Inc. Cambridge, MA, USA.

: The study was conducted according to the current guidelines for good and sound research practice after approval from the Dana-Farber Cancer Institute Office for Human Research Studies.

: Informed consent was obtained from all individual participants included in the study. Prior to any study procedures, all patients provided written informed consent for study participation.

: Included in patient consent for study.

: The study was conducted according to the current guidelines for good and sound research practice after approval from the Dana-Farber Cancer Institute Office for Human Research Studies.